bioMerieux (OTCMKTS:BMXMF) Shares Cross Above Fifty Day Moving Average - Should You Sell?

Key Points

• bioMerieux's stock price recently surpassed its 50-day moving average of $143.38, trading at a high of $149.00 with a low trading volume of just 15 shares.
• Royal Bank of Canada downgraded bioMerieux's rating from "moderate buy" to "hold", although the stock maintains a consensus rating of "Buy" from analysts.
• The company's financial metrics reflect a debt-to-equity ratio of 0.08 and a current ratio of 2.20, indicating strong liquidity and financial stability.

bioMerieux (OTCMKTS:BMXMF - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $143.38 and traded as high as $149.00. bioMerieux shares last traded at $149.00, with a volume of 15 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada downgraded shares of bioMerieux from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of "Hold".

bioMerieux Price Performance

The stock's 50 day moving average is $143.61 and its 200-day moving average is $132.70. The company has a quick ratio of 1.29, a current ratio of 2.20 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.